Published in Lab Law Weekly, January 26th, 2007
The granted license, which will remain valid for the lifetime of the patents, provides Illumina with certain rights with respect to SNP genotyping.
"OGT continues to develop its licensing program in the United States and is pleased to license Illumina to our sequence variation patents which is as part of OGT's broad patent portfolio. OGT's technology combined with Illumina's BeadArray technology gives customers access to an extremely powerful SNP detection platform," said Sue Sutton, vice...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.